The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option. In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use.
Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie
For information on open clinical trials please refer to the Cancer Trials Ireland website here and also to basket trials here.
Skin/Melanoma Chemotherapy Regimens
| Regimen Name |
Indication |
|
Avelumab Monotherapy
Regimen
|
00535a
Treatment of adult patients with metastatic Merkel cell carcinoma who have received 1 or more lines of chemotherapy for metastatic disease
|
|
Cobimetinib and Vemurafenib Therapy
Regimen
|
00373a
Cobimetinib in combination with vemurafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
|
|
Dabrafenib Monotherapy
Regimen
|
00237a
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
|
|
Dacarbazine Therapy
Regimen
|
00464a
Treatment of metastatic malignant melanoma.
|
|
Encorafenib and Binimetinib Therapy
Regimen
|
00563a
Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation
|
|
Ipilimumab monotherapy
Regimen
|
00105a
Treatment of adults with advanced (unresectable or metastatic) malignant melanoma.
|
|
Nivolumab 240mg Monotherapy - 14 Day
Regimen
|
00483a
As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.
00483f
As monotherapy for the adjuvant treatment of adults with melanoma with
involvement of lymph nodes or metastatic disease who have undergone
complete resection
|
|
Nivolumab 480mg Monotherapy - 28 Day
Regimen
|
00484a
As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.
00484c
As monotherapy for the adjuvant treatment of adults with melanoma with
involvement of lymph nodes or metastatic disease who have undergone
complete resection
|
|
Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy
Regimen
|
00431a
Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults
|
|
Nivolumab 3mg/kg Ipilimumab 1mg/kg Therapy
Regimen
|
00551b
Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults
|
|
Pembrolizumab 200mg Monotherapy
Regimen
|
00455b
As monotherapy for the treatment of adults with unresectable or advanced melanoma.
00455c
For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma.
00455g
As monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.
|
|
Pembrolizumab 400 mg Monotherapy
Regimen
|
00558b
As monotherapy for the treatment of adults with unresectable or advanced melanoma.
00558c
For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma
00558g
Adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection
|
|
Trametinib and Dabrafenib Therapy
Regimen
|
00415a<
Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
00415b
Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection
|
|
Vemurafenib Monotherapy
Regimen
|
00102a
Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
|
|
Vismodegib Monotherapy
Regimen
|
00236a
Treatment of adult patients with symptomatic metastatic basal cell carcinoma (MBCC)
00236b
Treatment of adult patients with local advanced basal cell carcinoma inappropriate for surgery or radiotherapy.
|
